Efficacy and safety of sitafloxacin (STFX) for low-risk febrile neutropenia in patients with lung cancer, phase II study,

Trial Profile

Efficacy and safety of sitafloxacin (STFX) for low-risk febrile neutropenia in patients with lung cancer, phase II study,

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jul 2013

At a glance

  • Drugs Sitafloxacin (Primary)
  • Indications Bacterial infections; Febrile neutropenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Jun 2013 New trial record
    • 17 Jun 2013 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top